Cara A. Rabik

Stanford University — United States

Medicine · Health Sciences

14h-index2.3kcitations50works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(31), Acute Lymphoblastic Leukemia research(16), Chronic Lymphocytic Leukemia Research(16), Metal complexes synthesis and properties(4), Acute Myeloid Leukemia Research(4)

Publications50 total

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on <i>TPMT</i> and <i>NUDT15</i> Genotypes: 2025 Update
Clinical Pharmacology & Therapeutics·2026Open Access
Supplementary Table S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S2 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S6 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Data from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Figure S4 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S7 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
Supplementary Table S1 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
2025Open Access
FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
Clinical Cancer Research·2025· 2 citedOpen Access
Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature
Pediatric Hematology and Oncology·2024· 2 cited
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated
Cancers·2023· 18 citedOpen Access
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
Journal of Clinical Oncology·2022· 71 citedOpen Access
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Blood Advances·2022· 50 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Patrick A. Brown(17), Michelle L. Hermiston(16), Theodore W. Laetsch(16), Vanessa A. Fabrizio(15), Christina Baggott(15), Snehit Prabhu(15), Jenna Rossoff(15), Amy Moskop(15), Michael R. Verneris(15), Nicole Karras(15), Muna Qayed(15), Prakash Satwani(15), Amy K. Keating(15), Vasant Chinnabhandar(15), Crystal L. Mackall(15), Liora M. Schultz(15), Shu Wang(15), Ritu Chadda(15), Donna Przepiorka(15), Jonathon Vallejo(15)